Ligand Pharmaceuticals Incorporated (LGND) - Stock Analysis
Last updated: Sep 6, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Clear recent catalyst and guidance upside: on 2026-04-27 Ligand acquired XOMA Royalty, expanding the royalty portfolio to more than 200 assets and seven commercial products, expected to be immediately accretive, while management raised 2026 adjusted EPS guidance to $8.50-$9.50.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠95% Gross Margin ⢠Strong Cash Liquidity ⢠Rising Debt Load LGND combines exceptional margins and strong liquidity with rising leverage, modest cash conversion, and premium valuationâwarranting caution despite robust profitability.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Firm support ⢠Key breakout Support Level: $280â$281 Resistance Level: $289â$291 LGND is mildly bearish over the last month, holding $280â$281 support but needing a break above $289â$291 to improve momentum; below $280 signals renewed downside.
Sentiment & News
Key News Insights: ⢠Royalty Asset Expansion ⢠$700M Deployable Capital ⢠Institutional Stake Increase Ligand's investor outreach, XOMA-driven royalty expansion, $700M capital capacity, and rising institutional ownership strengthen its growth outlook.
AI Summary
LGND is now a leveraged royalty-compounder, with XOMA making disciplined underwriting and cash-flow-backed accretionânot GAAP earningsâthe key test; at ~20x sales, investors should demand delivery on 2026â27 royalty growth and improved free-cash-flow conversion before adding aggressively.
Description
Ligand Pharmaceuticals develops or acquires technologies that support pharmaceutical companies in discovering and developing medicines, commercializing a portfolio that spans oncology, infectious disease, endocrine and bone health, vaccines, and other specialty treatments. The company also partners on and licenses programs in clinical development targeting cancer, neurological, metabolic, cardiovascular, and other conditions, and it manufactures Captisol excipient materials. Founded in 1987, Ligand is headquartered in Emeryville, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Apr 28 | May 5 | LGND | Ligand Pharmaceuticals Incorporated | Clear recent catalyst and guidance upside: on 2026-04-27 Ligand acquired XOMA Royalty, expanding the royalty portfolio to more than 200 assets and seven commercial products, expected to be immediately accretive, while management raised 2026 adjusted EPS guidance to $8.50-$9.50. | Closed | -0.0% |